<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03794856</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2018-0034</org_study_id>
    <nct_id>NCT03794856</nct_id>
  </id_info>
  <brief_title>The Dallas Asthma Brain and Cognition (ABC) Study</brief_title>
  <official_title>The Dallas Asthma Brain and Cognition (ABC) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern Methodist University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a chronic inflammatory airway disease that leads to episodic symptom exacerbations,&#xD;
      which exerts a substantial burden on quality of life and can influence other health domains&#xD;
      if not adequately controlled. Asthma prevalence rates have increased in the past decade,&#xD;
      affecting 8.4% (25.7 million people) of the United States population. The economic costs of&#xD;
      asthma have been estimated annually with $56 billion in the US alone. Despite progress in&#xD;
      pharmacological treatment, overall asthma control remains unsatisfactory and treatment&#xD;
      non-adherence is extremely high. Asthma is particularly under diagnosed and understudied in&#xD;
      aging adults. This problem will increase in coming decades given demographic trends and will&#xD;
      disproportionally contribute to the societal and personal economic costs associated with&#xD;
      asthma treatment and management. In the proposed 4-year project we will evaluate, in a&#xD;
      two-session assessment recruiting a total of 126 asthma patients and 66 healthy controls aged&#xD;
      40-69 years, the extent to which asthma and aging are associated with changes in cognition&#xD;
      and brain chemistry, structure, and function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will implement a cross-sectional design, conducted across two sessions. The first&#xD;
      session will capture cognitive performance, health history, and relevant social, behavioral,&#xD;
      and emotional processes. The second session approximately one week later will capture neural&#xD;
      structure, function, and chemistry. In the first session, participants will undergo screening&#xD;
      for psychological disorders, neuropsychological testing and pulmonary function assessment at&#xD;
      the Southern Methodist University (SMU) or UT Southwestern site. They will then participate&#xD;
      in a second session at University of Texas Southwestern Medical Center (UTSW) Advanced&#xD;
      Imaging Research Center (AIRC) with structural and functional magnetic resonance imaging&#xD;
      (MRI), diffusion tensor imaging (DTI), and brain metabolic activity with spectroscopy. Blood&#xD;
      draws and additional pre- and post-neuroimaging spirometry will also be performed at the&#xD;
      second session. Potential participants identified by brief phone screen will be invited for&#xD;
      two assessment sessions 1 week apart. At the first session, they will be consented,&#xD;
      interviewed about their asthma and/or general health status, and pulmonary function tests&#xD;
      will be performed. They will then fill in questionnaires and will be screened for&#xD;
      psychological disorders by standardized psychiatric interview. After that, they will complete&#xD;
      the neuropsychological test battery. The second session will entail spirometry (to ascertain&#xD;
      adequate lung function for imaging), the 1 ½ hour neuroimaging protocol, saliva samples, and&#xD;
      blood sampling. Spirometry will be repeated at the end of the imaging session. We will also&#xD;
      offer patients a brief optional session before the imaging session to get acquainted to the&#xD;
      scanning environment in a mock scanner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Examine processing speed of middle- to late-age adults with asthma with the Wechsler Adult Intelligence Scale (WAIS) Symbol Search Test.</measure>
    <time_frame>From date of baseline until the date of second session, approximately one week after baseline.</time_frame>
    <description>The Wechsler Adult Intelligence Scale (WAIS) Symbol Search test is a subtest of the WAIS, a scale widely used to measure intelligence. The examinee scans a search group of symbols and indicates whether one of the symbols matches a symbol in the target group. The time limit for this subtest is 120 seconds. The total raw score is the sum of the number of correct responses minus the number of incorrect responses. A higher score indicates better performance. The maximum total raw score is 60. If the total raw score is equal to or less than 0, then the total raw score is recorded as 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine executive functioning of middle- to late-age adults with asthma with the Trails A&amp;B test.</measure>
    <time_frame>From date of baseline until the date of second session, approximately one week after baseline.</time_frame>
    <description>The Trails A&amp;B test is a neuropsychological assessment. The task requires a subject to connect a sequence of 25 circles on a sheet of paper as quickly as possible. The test has 2 parts, with the first part of the test requiring the subject to connect circles that are all numbers (1, 2, 3, etc.) in order. The second part of the test requires that the subject alternates between numbers and letters (1, A, 2, B, etc.). The time taken for each part, measured in seconds, is the raw score. The score is then converted to a scaled score and a T score, both based on sex (male, female), race, and age. A higher score indicates better performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine working memory of middle- to late-age adults with asthma with the National Institute of Health (NIH) Sorting Working Memory Test.</measure>
    <time_frame>From date of baseline until the date of second session, approximately one week after baseline.</time_frame>
    <description>The National Institute of Health Sorting Working Memory Test is a computerized test that requires the subject to sequence sets of visually and auditorily presented stimuli (pictures of animals and food) in size order from smallest to biggest. There are two lists, with the 1-list version requiring sequencing among a single category (either animals or food), and the 2-list version (requiring sequencing of both food and animals within a series). The raw score is based on the sum of the correct across both lists, which comprise the List Sorting &quot;Total Score&quot;. The raw score is converted into a t-score (mean = 50, standard deviation = 10). A higher score indicates better performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine episodic memory of middle- to late-age adults with asthma with the Rey Auditory Verbal Learning Test (RAVLT).</measure>
    <time_frame>From date of baseline until the date of second session, approximately one week after baseline.</time_frame>
    <description>The examiner reads a list of 15 nouns aloud at the rate of one per second. The subject is asked to repeat all words they recall over 5 trials. An interference list (List B) is then read and subject is asked to recall. Immediately following the interference trial, the subject is asked to recall words from List A (Trial 6). After a 20 minute delay the subject is asked to recall as many words as possible from the first list (delayed recall). A list of 50 words is presented containing all words from List A and the subject is asked to indicate whether each word was on List A (recognition task). The total score (Trials 1-5) is calculated by summing the correct number of words for each trial. List B, Trial 6 and Delayed Recall are calculated by summing the correct number of words. Recognition task is scored by taking the number of correct words and subtracting the number of false positive words. Scores are converted into t-scores with higher score indicating better performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine reasoning of middle- to late-age adults with asthma with the National Adult Reading Test (NART).</measure>
    <time_frame>From date of baseline until the date of second session, approximately one week after baseline.</time_frame>
    <description>The National Adult Reading Test is a commonly used test to measure intellectual ability in English-speaking patients. A list of 50 words, whose pronunciation cannot be determined from their spelling, are given to the subject and the subject is asked to read down the list. The examiner marks whether the subject pronounced the word correctly and the NART is scored by summing the number of words pronounced correctly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine brain function of adult asthma patients from age 40-69 with functional magnetic resonance imaging (fMRI)</measure>
    <time_frame>From date of baseline until the date of second session, approximately one week after baseline.</time_frame>
    <description>We will assess brain functioning by measuring default brain network connectivity using functional magnetic resonance imaging (fMRI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine brain structure of adult asthma patients from age 40-69 with structural magnetic resonance imaging (sMRI)</measure>
    <time_frame>From date of baseline until the date of second session, approximately one week after baseline.</time_frame>
    <description>We will assess brain structure, hippocampal gray matter volume, using structural magnetic resonance imaging (sMRI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine brain chemistry of adult asthma patients from age 40-69 with proton magnetic resonance spectroscopy (1H-MRS)</measure>
    <time_frame>From date of baseline until the date of second session, approximately one week after baseline.</time_frame>
    <description>We will assess brain chemistry, specifically differences in hippocampal metabolite levels, using proton magnetic resonance spectroscopy (1H-MRS)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Asthma patients</arm_group_label>
    <description>Asthma patients will undergo behavioral testing and imaging at a single timepoint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <description>Healthy volunteers will undergo behavioral testing and imaging at a single timepoint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional and Structural Magnetic Resonance Imaging (research grade)</intervention_name>
    <description>Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.</description>
    <arm_group_label>Asthma patients</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Function Testing (non-diagnostic)</intervention_name>
    <description>Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.</description>
    <arm_group_label>Asthma patients</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Asthma and Psychological Questionnaires (non-diagnostic)</intervention_name>
    <description>Participants will fill out asthma and psychological questionnaires (non-diagnostic)</description>
    <arm_group_label>Asthma patients</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the larger Dallas/ Fort Worth community. We will recruit&#xD;
        both healthy controls and subjects with asthma through local flyers, online advertisements,&#xD;
        at community allergy and pulmonary clinics, and databases. Individuals who appear eligible&#xD;
        will be invited to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For asthma patients: diagnosis of asthma (verified by a medical documentation) for at&#xD;
             least 2 years; for healthy volunteers: no significant medical or psychiatric history.&#xD;
&#xD;
          -  Ages 40 to 69 years old.&#xD;
&#xD;
          -  Proficient in English.&#xD;
&#xD;
          -  Education level of at least 10th grade level.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with oral corticosteroids in the previous 6 weeks, because of the potent&#xD;
             effects of this drug on airway reactivity.&#xD;
&#xD;
          -  Spirometry: Peak expiratory flow (PEF) below 60% of predicted.&#xD;
&#xD;
          -  Diagnosis of vocal cord dysfunction (identified by abnormalities in spirometric&#xD;
             flow-volume curves), clinically significant chronic obstructive pulmonary disease, or&#xD;
             emphysema.&#xD;
&#xD;
          -  Presence or history of medical or neurological disorder that may affect brain function&#xD;
             and the physiological systems of interest (e.g. angina, myocardial infarction,&#xD;
             congestive heart failure, transient ischemic attacks, cerebrovascular accidents,&#xD;
             emphysema, or chronic obstructive pulmonary disease, history of seizures or head&#xD;
             trauma, endocrine disorders or renal disease, chemotherapy or radiation presently or&#xD;
             in the past 5 years, uncontrolled diabetes, blood pressure above 160/90 (self-reported&#xD;
             or measured at session 1).&#xD;
&#xD;
          -  Corrected vision poorer than 20/30 on Snellen Eye Chart.&#xD;
&#xD;
          -  Presence or history of Schizophrenia, Psychosis, Dementia, Bipolar I, Bipolar II, PTSD&#xD;
             or Acute Stress Disorder&#xD;
&#xD;
          -  Current or recent history (within 1 year) of Substance Related Disorders, current&#xD;
             recreational drug use (defined as past 30 days) or consuming more than 20 alcoholic&#xD;
             drinks per week.&#xD;
&#xD;
          -  Current treatment with anti-psychotics, sedatives, benzodiazepines with a half-life&#xD;
             longer than 6 hours.&#xD;
&#xD;
          -  Previous electroconvulsive therapy.&#xD;
&#xD;
          -  Presence of history of orthopaedic circumstances and metallic inserts interfering with&#xD;
             MR scanning (prior surgeries and/or implant pacemakers, pacemaker wires, artificial&#xD;
             heart value, brain aneurysm surgery, middle ear implant, non-removable hearing aid or&#xD;
             jewelry, braces or extensive dental work, cataract surgery or lens implant, implanted&#xD;
             mechanical or electrical device, artificial limb or joint, foreign metallic objects in&#xD;
             the body such as bullets, BB's, shrapnel, or metalwork fragments, pregnancy,&#xD;
             claustrophobia, uncontrollable shaking, or inability to lie still for one hour.&#xD;
&#xD;
          -  Not proficient in English.&#xD;
&#xD;
          -  In the opinion of the principal investigator, participant is otherwise unsuitable for&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Sherwood Brown, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haneen Khan</last_name>
    <phone>214-645-6960</phone>
    <email>haneen.khan@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Methodist University</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Berthet-Miron, M.Psy</last_name>
      <phone>214-768-2186</phone>
      <email>mberthetmirn@smu.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Ritz, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E. Sherwood Brown, MD, PhD</last_name>
      <phone>214-645-6950</phone>
      <email>sherwood.brown@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>E. Sherwood Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>February 14, 2023</last_update_submitted>
  <last_update_submitted_qc>February 14, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Sherwood Brown, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Healthy participants</keyword>
  <keyword>Asthma</keyword>
  <keyword>Cognitive functioning</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03794856
org study id: STU-2018-0034
nct id: NCT03794856
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Asthma is a chronic inflammatory airway disease that leads to episodic symptom exacerbations,
      which exerts a substantial burden on quality of life and can influence other health domains
      if not adequately controlled. Asthma prevalence rates have increased in the past decade,
      affecting 8.4% (25.7 million people) of the United States population. The economic costs of
      asthma have been estimated annually with $56 billion in the US alone. Despite progress in
      pharmacological treatment, overall asthma control remains unsatisfactory and treatment
      non-adherence is extremely high. Asthma is particularly under diagnosed and understudied in
      aging adults. This problem will increase in coming decades given demographic trends and will
      disproportionally contribute to the societal and personal economic costs associated with
      asthma treatment and management. In the proposed 4-year project we will evaluate, in a
      two-session assessment recruiting a total of 126 asthma patients and 66 healthy controls aged
      40-69 years, the extent to which asthma and aging are associated with changes in cognition
      and brain chemistry, structure, and function.
This study will implement a cross-sectional design, conducted across two sessions. The first
      session will capture cognitive performance, health history, and relevant social, behavioral,
      and emotional processes. The second session approximately one week later will capture neural
      structure, function, and chemistry. In the first session, participants will undergo screening
      for psychological disorders, neuropsychological testing and pulmonary function assessment at
      the Southern Methodist University (SMU) or UT Southwestern site. They will then participate
      in a second session at University of Texas Southwestern Medical Center (UTSW) Advanced
      Imaging Research Center (AIRC) with structural and functional magnetic resonance imaging
      (MRI), diffusion tensor imaging (DTI), and brain metabolic activity with spectroscopy. Blood
      draws and additional pre- and post-neuroimaging spirometry will also be performed at the
      second session. Potential participants identified by brief phone screen will be invited for
      two assessment sessions 1 week apart. At the first session, they will be consented,
      interviewed about their asthma and/or general health status, and pulmonary function tests
      will be performed. They will then fill in questionnaires and will be screened for
      psychological disorders by standardized psychiatric interview. After that, they will complete
      the neuropsychological test battery. The second session will entail spirometry (to ascertain
      adequate lung function for imaging), the 1 ½ hour neuroimaging protocol, saliva samples, and
      blood sampling. Spirometry will be repeated at the end of the imaging session. We will also
      offer patients a brief optional session before the imaging session to get acquainted to the
      scanning environment in a mock scanner.
observational model: Case-Control
time perspective: Cross-Sectional
measure: Examine processing speed of middle- to late-age adults with asthma with the Wechsler Adult Intelligence Scale (WAIS) Symbol Search Test.
time frame: From date of baseline until the date of second session, approximately one week after baseline.
description: The Wechsler Adult Intelligence Scale (WAIS) Symbol Search test is a subtest of the WAIS, a scale widely used to measure intelligence. The examinee scans a search group of symbols and indicates whether one of the symbols matches a symbol in the target group. The time limit for this subtest is 120 seconds. The total raw score is the sum of the number of correct responses minus the number of incorrect responses. A higher score indicates better performance. The maximum total raw score is 60. If the total raw score is equal to or less than 0, then the total raw score is recorded as 0.
measure: Examine executive functioning of middle- to late-age adults with asthma with the Trails A&B test.
time frame: From date of baseline until the date of second session, approximately one week after baseline.
description: The Trails A&B test is a neuropsychological assessment. The task requires a subject to connect a sequence of 25 circles on a sheet of paper as quickly as possible. The test has 2 parts, with the first part of the test requiring the subject to connect circles that are all numbers (1, 2, 3, etc.) in order. The second part of the test requires that the subject alternates between numbers and letters (1, A, 2, B, etc.). The time taken for each part, measured in seconds, is the raw score. The score is then converted to a scaled score and a T score, both based on sex (male, female), race, and age. A higher score indicates better performance.
measure: Examine working memory of middle- to late-age adults with asthma with the National Institute of Health (NIH) Sorting Working Memory Test.
time frame: From date of baseline until the date of second session, approximately one week after baseline.
description: The National Institute of Health Sorting Working Memory Test is a computerized test that requires the subject to sequence sets of visually and auditorily presented stimuli (pictures of animals and food) in size order from smallest to biggest. There are two lists, with the 1-list version requiring sequencing among a single category (either animals or food), and the 2-list version (requiring sequencing of both food and animals within a series). The raw score is based on the sum of the correct across both lists, which comprise the List Sorting "Total Score". The raw score is converted into a t-score (mean = 50, standard deviation = 10). A higher score indicates better performance.
measure: Examine episodic memory of middle- to late-age adults with asthma with the Rey Auditory Verbal Learning Test (RAVLT).
time frame: From date of baseline until the date of second session, approximately one week after baseline.
description: The examiner reads a list of 15 nouns aloud at the rate of one per second. The subject is asked to repeat all words they recall over 5 trials. An interference list (List B) is then read and subject is asked to recall. Immediately following the interference trial, the subject is asked to recall words from List A (Trial 6). After a 20 minute delay the subject is asked to recall as many words as possible from the first list (delayed recall). A list of 50 words is presented containing all words from List A and the subject is asked to indicate whether each word was on List A (recognition task). The total score (Trials 1-5) is calculated by summing the correct number of words for each trial. List B, Trial 6 and Delayed Recall are calculated by summing the correct number of words. Recognition task is scored by taking the number of correct words and subtracting the number of false positive words. Scores are converted into t-scores with higher score indicating better performance.
measure: Examine reasoning of middle- to late-age adults with asthma with the National Adult Reading Test (NART).
time frame: From date of baseline until the date of second session, approximately one week after baseline.
description: The National Adult Reading Test is a commonly used test to measure intellectual ability in English-speaking patients. A list of 50 words, whose pronunciation cannot be determined from their spelling, are given to the subject and the subject is asked to read down the list. The examiner marks whether the subject pronounced the word correctly and the NART is scored by summing the number of words pronounced correctly.
measure: Examine brain function of adult asthma patients from age 40-69 with functional magnetic resonance imaging (fMRI)
time frame: From date of baseline until the date of second session, approximately one week after baseline.
description: We will assess brain functioning by measuring default brain network connectivity using functional magnetic resonance imaging (fMRI)
measure: Examine brain structure of adult asthma patients from age 40-69 with structural magnetic resonance imaging (sMRI)
time frame: From date of baseline until the date of second session, approximately one week after baseline.
description: We will assess brain structure, hippocampal gray matter volume, using structural magnetic resonance imaging (sMRI)
measure: Examine brain chemistry of adult asthma patients from age 40-69 with proton magnetic resonance spectroscopy (1H-MRS)
time frame: From date of baseline until the date of second session, approximately one week after baseline.
description: We will assess brain chemistry, specifically differences in hippocampal metabolite levels, using proton magnetic resonance spectroscopy (1H-MRS)
arm group label: Asthma patients
description: Asthma patients will undergo behavioral testing and imaging at a single timepoint.
arm group label: Healthy Volunteers
description: Healthy volunteers will undergo behavioral testing and imaging at a single timepoint.
intervention type: Other
intervention name: Functional and Structural Magnetic Resonance Imaging (research grade)
description: Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.
arm group label: Asthma patients
arm group label: Healthy Volunteers
intervention type: Other
intervention name: Cognitive Function Testing (non-diagnostic)
description: Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.
arm group label: Asthma patients
arm group label: Healthy Volunteers
intervention type: Other
intervention name: Asthma and Psychological Questionnaires (non-diagnostic)
description: Participants will fill out asthma and psychological questionnaires (non-diagnostic)
arm group label: Asthma patients
arm group label: Healthy Volunteers
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 40 Years
maximum age: 69 Years
healthy volunteers: Accepts Healthy Volunteers
last name: E. Sherwood Brown, MD, PhD
role: Principal Investigator
affiliation: UT Southwestern Medical Center
last name: Haneen Khan
phone: 214-645-6960
email: haneen.khan@utsouthwestern.edu
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
country: United States
responsible party type: Principal Investigator
investigator affiliation: University of Texas Southwestern Medical Center
investigator full name: Sherwood Brown, MD, PhD
investigator title: Professor of Medicine
mesh term: Asthma
sharing ipd: No